Criteria for Evaluation of Novel Markers of Cardiovascular Risk
Mark A. Hlatky(Cardiovascular Institute of the South), Peter W.F. Wilson(VA Tennessee Valley Healthcare System), Philip Greenland(Northwestern University), Barbara V. Howard(MedStar Health), Mitchell S.V. Elkind(Columbia University), Alan S. Go(Kaiser Permanente), Donna K. Arnett(University of Alabama at Birmingham), Christopher M. Kramer(American College of Cardiology), Frank E. Harrell(Vanderbilt University Medical Center), Priscilla Y. Hsue(University of California, Los Angeles), Christie M. Ballantyne(Baylor College of Medicine), Sidney C. Smith(University of North Carolina at Chapel Hill), Sharon‐Lise T. Normand(Harvard University), Virginia J. Howard(University of Alabama at Birmingham), Christopher J. O’Donnell(Harvard University), Yuling Hong(National Heart Lung and Blood Institute), Joseph P. McConnell(Medical Diagnostic Laboratories (United States)), Michael H. Criqui(University of California San Diego)
Cited by 1,132
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Prediction of Coronary Heart Disease Using Risk Factor Categories
|Circulation|1998|9.6k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k